France· FR:60314272
ARTIREM 0,0025 mmol/mL, solution injectable en seringue préremplie
A medicinal product containing oxyde de gadolinium + dota, registered in France by GUERBET, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- OXYDE DE GADOLINIUM + DOTA
- Manufacturer
- GUERBET
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009359913861 seringue(s) préremplie(s) en verre de 20 mlEUR 43.46
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bceb4cd9-ffdc-485c-aaa1-8a64413e698e GET /v1/drugs/bceb4cd9-ffdc-485c-aaa1-8a64413e698e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60314272",
"date_amm": "2002-07-31",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "OXYDE DE GADOLINIUM + DOTA",
"statut_amm": "Autorisation abrogée",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "solution injectable",
"voies_administration": "intraarticulaire",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about oxyde de gadolinium + dota.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.